Ftse Mib
38.592,81
-0,48%
DAX
23.008,94
-1,87%
S&P 500
5.770,20
0,55%
NASDAQ
18.196,22
0,70%
Bitcoin
86.285,40
0,15%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kazia Therapeutics Ltd (KZIA) Kazia Therapeutics Ltd (KZIA) Notizie

KZIA

Kazia Therapeutics (KZIA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KZIA
DataOraFonteTitoloSimboloCompagnia
21/02/202512:33Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
20/02/202522:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
20/02/202514:46PR Newswire (US)Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's DiseaseNASDAQ:KZIAKazia Therapeutics Ltd
06/02/202506:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
30/01/202522:31Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
30/01/202513:30PR Newswire (US)Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancerNASDAQ:KZIAKazia Therapeutics Ltd
17/01/202522:30Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
16/01/202516:40Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KZIAKazia Therapeutics Ltd
14/01/202522:00PR Newswire (US)Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
13/01/202514:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
10/01/202515:58PR Newswire (US)Kazia Therapeutics Announces $2.0 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
31/12/202414:00PR Newswire (US)Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDANASDAQ:KZIAKazia Therapeutics Ltd
11/12/202414:00PR Newswire (US)Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer SymposiumNASDAQ:KZIAKazia Therapeutics Ltd
27/11/202422:30Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:KZIAKazia Therapeutics Ltd
15/11/202422:02Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:KZIAKazia Therapeutics Ltd
14/11/202422:19Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KZIAKazia Therapeutics Ltd
07/11/202401:53Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KZIAKazia Therapeutics Ltd
04/11/202413:30PR Newswire (US)Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma MultiformeNASDAQ:KZIAKazia Therapeutics Ltd
01/11/202421:05Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:KZIAKazia Therapeutics Ltd
24/10/202414:22Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:KZIAKazia Therapeutics Ltd
02/10/202414:45PR Newswire (US)Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society foNASDAQ:KZIAKazia Therapeutics Ltd
23/09/202414:30PR Newswire (US)Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research SymposiumNASDAQ:KZIAKazia Therapeutics Ltd
12/09/202413:30PR Newswire (US)KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFERNASDAQ:KZIAKazia Therapeutics Ltd
10/07/202416:35AllPennyStocks.comBiotech Experiences Strong Open Following Major AnnouncementNASDAQ:KZIAKazia Therapeutics Ltd
10/07/202413:30PR Newswire (US)Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in GlioblastomaNASDAQ:KZIAKazia Therapeutics Ltd
27/06/202414:15PR Newswire (US)KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCERNASDAQ:KZIAKazia Therapeutics Ltd
23/05/202420:41PR Newswire (US)Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementNASDAQ:KZIAKazia Therapeutics Ltd
01/05/202414:45PR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSNASDAQ:KZIAKazia Therapeutics Ltd
21/03/202413:52PR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesNASDAQ:KZIAKazia Therapeutics Ltd
13/03/202413:00PR Newswire (US)Kazia announces presentation of new data at AACR Annual MeetingNASDAQ:KZIAKazia Therapeutics Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KZIA

La tua Cronologia

BOV
DHER34M
Donaher
USOTC
GRYCF
Graycliff Exploration (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci